Swiss investment firm Sectoral Asset Management has launched a new biotech strategy, the Variopartner SICAV – Sectoral Biotech Opportunities Fund with initial assets of over $50m (€44.1m). The fund invests in innovative biotech companies and focuses on small and mid caps. Its portfolio consists of 30 high conviction positions and the stock selection applies a bottom-up approach. […]